AIMS/HYPOTHESIS: Genetic variation in the melatonin receptor 1B (MTNR1B) is associated with type 2 diabetes. Melatonin contributes to the regulation of sleep, and sleep problems are a documented risk factor for type 2 diabetes. The aim of this study was to investigate whether the MTNR1B gene variant rs10830963 is associated with sleep problems and whether this variant contributes to the association between sleep disturbances and type 2 diabetes. METHODS: This was a case-control study nested within the population-based Nord-Trøndelag Health Study, including 1,322 prevalent cases of type 2 diabetes and 1,447 controls. In addition, prospective data were available for 838 incident cases and 1,133 controls. Genotyping was done by TaqMan single-nucleotide polymorphism allelic discrimination analysis. ORs and 95% CIs were calculated using logistic regression models. RESULTS: Our findings confirm an association between sleep disturbances and type 2 diabetes (OR 1.69, 95% CI 1.22-2.33, p = 0.0016) and between the risk allele of rs10830963 and type 2 diabetes (OR 1.12, 95% CI 1.00-1.27, p = 0.0579). There was a tendency for an association between the risk allele and prevalence of sleep problems (specifically early awakening). However, the risk allele did not influence the association of sleep problems with diabetes, which was unaltered after adjustment for the MTNR1B risk allele (OR 1.69, 95% CI 1.23-2.34, p = 0.0014). Results based on prospective data were similar, although non-significant. CONCLUSIONS/ INTERPRETATION: Our findings do not support participation of the MTNR1B gene variant rs10830963 in the well documented association between sleep disturbances and type 2 diabetes.
AIMS/HYPOTHESIS: Genetic variation in the melatonin receptor 1B (MTNR1B) is associated with type 2 diabetes. Melatonin contributes to the regulation of sleep, and sleep problems are a documented risk factor for type 2 diabetes. The aim of this study was to investigate whether the MTNR1B gene variant rs10830963 is associated with sleep problems and whether this variant contributes to the association between sleep disturbances and type 2 diabetes. METHODS: This was a case-control study nested within the population-based Nord-Trøndelag Health Study, including 1,322 prevalent cases of type 2 diabetes and 1,447 controls. In addition, prospective data were available for 838 incident cases and 1,133 controls. Genotyping was done by TaqMan single-nucleotide polymorphism allelic discrimination analysis. ORs and 95% CIs were calculated using logistic regression models. RESULTS: Our findings confirm an association between sleep disturbances and type 2 diabetes (OR 1.69, 95% CI 1.22-2.33, p = 0.0016) and between the risk allele of rs10830963 and type 2 diabetes (OR 1.12, 95% CI 1.00-1.27, p = 0.0579). There was a tendency for an association between the risk allele and prevalence of sleep problems (specifically early awakening). However, the risk allele did not influence the association of sleep problems with diabetes, which was unaltered after adjustment for the MTNR1B risk allele (OR 1.69, 95% CI 1.23-2.34, p = 0.0014). Results based on prospective data were similar, although non-significant. CONCLUSIONS/ INTERPRETATION: Our findings do not support participation of the MTNR1B gene variant rs10830963 in the well documented association between sleep disturbances and type 2 diabetes.
Authors: Valeriya Lyssenko; Cecilia L F Nagorny; Michael R Erdos; Nils Wierup; Anna Jonsson; Peter Spégel; Marco Bugliani; Richa Saxena; Malin Fex; Nicolo Pulizzi; Bo Isomaa; Tiinamaija Tuomi; Peter Nilsson; Johanna Kuusisto; Jaakko Tuomilehto; Michael Boehnke; David Altshuler; Frank Sundler; Johan G Eriksson; Anne U Jackson; Markku Laakso; Piero Marchetti; Richard M Watanabe; Hindrik Mulder; Leif Groop Journal: Nat Genet Date: 2008-12-07 Impact factor: 38.330
Authors: Nabila Bouatia-Naji; Amélie Bonnefond; Christine Cavalcanti-Proença; Thomas Sparsø; Johan Holmkvist; Marion Marchand; Jérôme Delplanque; Stéphane Lobbens; Ghislain Rocheleau; Emmanuelle Durand; Franck De Graeve; Jean-Claude Chèvre; Knut Borch-Johnsen; Anna-Liisa Hartikainen; Aimo Ruokonen; Jean Tichet; Michel Marre; Jacques Weill; Barbara Heude; Maithé Tauber; Katleen Lemaire; Frans Schuit; Paul Elliott; Torben Jørgensen; Guillaume Charpentier; Samy Hadjadj; Stéphane Cauchi; Martine Vaxillaire; Robert Sladek; Sophie Visvikis-Siest; Beverley Balkau; Claire Lévy-Marchal; François Pattou; David Meyre; Alexandra I F Blakemore; Marjo-Riita Jarvelin; Andrew J Walley; Torben Hansen; Christian Dina; Oluf Pedersen; Philippe Froguel Journal: Nat Genet Date: 2008-12-07 Impact factor: 38.330
Authors: John C Chambers; Weihua Zhang; Delilah Zabaneh; Joban Sehmi; Piyush Jain; Mark I McCarthy; Philippe Froguel; Aimo Ruokonen; David Balding; Marjo-Riitta Jarvelin; James Scott; Paul Elliott; Jaspal S Kooner Journal: Diabetes Date: 2009-08-03 Impact factor: 9.461
Authors: Hanna M Ollila; Erkki Kronholm; Johannes Kettunen; Kaisa Silander; Markus Perola; Tarja Porkka-Heiskanen; Veikko Salomaa; Tiina Paunio Journal: Diabetologia Date: 2016-02-24 Impact factor: 10.122
Authors: Archana Tare; Jacqueline M Lane; Brian E Cade; Struan F A Grant; Ting-Hsu Chen; Naresh M Punjabi; Diane S Lauderdale; Phyllis C Zee; Sina A Gharib; Daniel J Gottlieb; Frank A J L Scheer; Susan Redline; Richa Saxena Journal: Diabetologia Date: 2013-11-27 Impact factor: 10.122